DK3060229T3 - Stabile, vandige antistofformuleringer - Google Patents
Stabile, vandige antistofformuleringer Download PDFInfo
- Publication number
- DK3060229T3 DK3060229T3 DK14855343.1T DK14855343T DK3060229T3 DK 3060229 T3 DK3060229 T3 DK 3060229T3 DK 14855343 T DK14855343 T DK 14855343T DK 3060229 T3 DK3060229 T3 DK 3060229T3
- Authority
- DK
- Denmark
- Prior art keywords
- stable
- antibody formulations
- water
- water antibody
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895143P | 2013-10-24 | 2013-10-24 | |
| PCT/US2014/061997 WO2015061584A1 (en) | 2013-10-24 | 2014-10-23 | Stable, aqueous antibody formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3060229T3 true DK3060229T3 (da) | 2021-10-11 |
Family
ID=52993565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14855343.1T DK3060229T3 (da) | 2013-10-24 | 2014-10-23 | Stabile, vandige antistofformuleringer |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US20150118249A1 (da) |
| EP (2) | EP3892288A1 (da) |
| JP (3) | JP6483673B2 (da) |
| KR (3) | KR102109053B1 (da) |
| CN (4) | CN105611938B (da) |
| AU (4) | AU2014339984B2 (da) |
| BR (1) | BR112016008576B1 (da) |
| CA (1) | CA2926089C (da) |
| CY (1) | CY1125697T1 (da) |
| DK (1) | DK3060229T3 (da) |
| ES (1) | ES2893861T3 (da) |
| HR (1) | HRP20211371T1 (da) |
| HU (1) | HUE055919T2 (da) |
| LT (1) | LT3060229T (da) |
| MX (2) | MX388893B (da) |
| PL (1) | PL3060229T3 (da) |
| PT (1) | PT3060229T (da) |
| RS (1) | RS62419B1 (da) |
| RU (2) | RU2763787C2 (da) |
| SG (2) | SG11201603206UA (da) |
| SI (1) | SI3060229T1 (da) |
| SM (1) | SMT202100580T1 (da) |
| WO (1) | WO2015061584A1 (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2776657T3 (es) | 2005-06-14 | 2020-07-31 | Amgen Inc | Formulaciones de proteínas autotamponantes |
| US9159537B2 (en) * | 2012-05-03 | 2015-10-13 | University Of Notre Dame Du Lac | Method for analyzing sample components |
| TWI595007B (zh) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | 抗mcam抗體及相關使用方法 |
| CN105611938B (zh) * | 2013-10-24 | 2024-12-31 | 阿斯利康(瑞典)有限公司 | 稳定的水性抗体配制品 |
| US10059761B2 (en) | 2014-03-12 | 2018-08-28 | Prothena Biosciences Limited | Anti-Laminin4 antibodies specific for LG4-5 |
| EP3116911B8 (en) | 2014-03-12 | 2019-10-23 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| JP2018530540A (ja) * | 2015-09-16 | 2018-10-18 | プロセナ バイオサイエンシーズ リミテッド | 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗mcam抗体の使用 |
| EP4606820A3 (en) * | 2015-11-30 | 2025-10-29 | Medimmune, LLC | Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
| TWI656882B (zh) * | 2016-08-10 | 2019-04-21 | 南韓商賽特瑞恩股份有限公司 | 穩定的液體抗流感病毒抗體醫藥調配物 |
| WO2018075818A1 (en) * | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical formulations and methods of making the same |
| WO2019086463A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| AU2019329686A1 (en) | 2018-08-27 | 2020-12-03 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
| US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
| AU2020251627A1 (en) * | 2019-03-29 | 2021-11-11 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition containing antibody against IL-5 and use thereof |
| TW202126688A (zh) | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
| WO2021124793A1 (ja) * | 2019-12-16 | 2021-06-24 | ニプロ株式会社 | 凝集防止剤ならびにそれを用いた医薬組成物および医療用デバイス |
| CN111024963A (zh) * | 2019-12-27 | 2020-04-17 | 桂林英美特生物技术研究所 | 一种液体稳定、抗冰冻的免疫比浊法载脂蛋白b单试剂 |
| WO2021182874A1 (ko) * | 2020-03-13 | 2021-09-16 | 삼성바이오에피스 주식회사 | 안정성이 증진된 액상 약제학적 조성물 |
| CN113769081A (zh) * | 2020-06-10 | 2021-12-10 | 三生国健药业(上海)股份有限公司 | 一种稳定的高浓度抗人il-5单克隆抗体液体制剂 |
| WO2022025030A1 (ja) * | 2020-07-28 | 2022-02-03 | 中外製薬株式会社 | 新規改変型抗体を含む、針シールドを備えた針付プレフィルドシリンジ製剤 |
| KR20230121797A (ko) * | 2020-12-17 | 2023-08-21 | 아스트라제네카 아베 | 항-il5r 항체 제형 |
| WO2026027944A1 (en) * | 2024-07-30 | 2026-02-05 | Sairopa B.V. | Anti-sirp alpha antibody formulations and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE120454T1 (de) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
| ES2178635T3 (es) | 1990-11-09 | 2003-01-01 | Stephen D Gillies | Inmunoconjugados de citoquinas. |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| DE69633973T2 (de) * | 1995-09-11 | 2005-12-22 | Kyowa Hakko Kogyo Co., Ltd. | Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor |
| EP1539212A4 (en) * | 2002-07-12 | 2007-05-02 | Medarex Inc | METHOD AND COMPOSITIONS FOR PREVENTING OXIDATIVE DEGRADATION OF PROTEINS |
| CA2526983C (en) * | 2003-05-26 | 2010-08-10 | Woo In Baik | Disposable syringe |
| DE202006001995U1 (de) * | 2006-02-07 | 2006-06-08 | Sarstedt Ag & Co. | Probengefäß zur Aufnahme von kleinen Flüssigkeitsmengen für Analysen |
| BRPI0710826A2 (pt) * | 2006-04-21 | 2011-08-23 | Novartis Ag | composições farmacêuticas de anticorpo anti-cd40 antagonista |
| CN101541345A (zh) * | 2006-09-25 | 2009-09-23 | 米迪缪尼有限公司 | 稳定化的抗体制剂和其应用 |
| US20100209434A1 (en) * | 2007-03-30 | 2010-08-19 | Medimmune, Llc | Antibody formulation |
| SG10202000728UA (en) | 2007-05-14 | 2020-03-30 | Astrazeneca Ab | Methods of reducing eosinophil levels |
| SG2014011365A (en) * | 2008-09-19 | 2014-05-29 | Hoffmann La Roche | Novel antibody formulation |
| PE20120359A1 (es) * | 2009-03-06 | 2012-04-13 | Genentech Inc | Formulacion con anticuerpo |
| SG10201401995UA (en) * | 2009-05-04 | 2014-08-28 | Abbvie Biotechnology Ltd | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| HK1200721A1 (en) * | 2011-10-18 | 2015-08-14 | 科荣生生物科学公司 | Etanercept formulations stabilized with xylitol |
| EP2771358A4 (en) * | 2011-10-26 | 2015-08-26 | Bio Rad Laboratories | ELIMINATION OF VIRAL AGENTS IN MIXED MODE CHROMATOGRAPHY |
| CA2853823C (en) * | 2011-10-28 | 2016-12-20 | Integritybio Inc. | Protein formulations containing amino acids |
| KR20140097217A (ko) * | 2011-11-01 | 2014-08-06 | 메디뮨 엘엘씨 | 급성 천식 악화의 빈도 및 중증도를 감소시키는 방법 |
| KR20220057637A (ko) * | 2013-08-12 | 2022-05-09 | 아스트라제네카 아베 | 벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법 |
| SMT201900311T1 (it) * | 2013-08-12 | 2019-07-11 | Astrazeneca Ab | Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab |
| CN105611938B (zh) * | 2013-10-24 | 2024-12-31 | 阿斯利康(瑞典)有限公司 | 稳定的水性抗体配制品 |
-
2014
- 2014-10-23 CN CN201480055263.0A patent/CN105611938B/zh active Active
- 2014-10-23 EP EP20207556.0A patent/EP3892288A1/en active Pending
- 2014-10-23 LT LTEPPCT/US2014/061997T patent/LT3060229T/lt unknown
- 2014-10-23 SI SI201431876T patent/SI3060229T1/sl unknown
- 2014-10-23 EP EP14855343.1A patent/EP3060229B1/en active Active
- 2014-10-23 SG SG11201603206UA patent/SG11201603206UA/en unknown
- 2014-10-23 SG SG10201803178UA patent/SG10201803178UA/en unknown
- 2014-10-23 HU HUE14855343A patent/HUE055919T2/hu unknown
- 2014-10-23 ES ES14855343T patent/ES2893861T3/es active Active
- 2014-10-23 BR BR112016008576-0A patent/BR112016008576B1/pt active IP Right Grant
- 2014-10-23 AU AU2014339984A patent/AU2014339984B2/en active Active
- 2014-10-23 KR KR1020167012565A patent/KR102109053B1/ko active Active
- 2014-10-23 US US14/521,870 patent/US20150118249A1/en not_active Abandoned
- 2014-10-23 KR KR1020217009731A patent/KR20210041101A/ko not_active Ceased
- 2014-10-23 CN CN202411964617.5A patent/CN119971024A/zh active Pending
- 2014-10-23 PL PL14855343T patent/PL3060229T3/pl unknown
- 2014-10-23 HR HRP20211371TT patent/HRP20211371T1/hr unknown
- 2014-10-23 KR KR1020207012828A patent/KR102238065B1/ko active Active
- 2014-10-23 MX MX2016004605A patent/MX388893B/es unknown
- 2014-10-23 JP JP2016525876A patent/JP6483673B2/ja active Active
- 2014-10-23 RU RU2016119755A patent/RU2763787C2/ru active
- 2014-10-23 RS RS20211238A patent/RS62419B1/sr unknown
- 2014-10-23 CA CA2926089A patent/CA2926089C/en active Active
- 2014-10-23 SM SM20210580T patent/SMT202100580T1/it unknown
- 2014-10-23 CN CN202110799711.XA patent/CN113350278B/zh active Active
- 2014-10-23 DK DK14855343.1T patent/DK3060229T3/da active
- 2014-10-23 PT PT14855343T patent/PT3060229T/pt unknown
- 2014-10-23 CN CN202010809794.1A patent/CN112107538A/zh active Pending
- 2014-10-23 WO PCT/US2014/061997 patent/WO2015061584A1/en not_active Ceased
- 2014-10-23 RU RU2021137159A patent/RU2021137159A/ru unknown
-
2016
- 2016-04-11 MX MX2021015825A patent/MX2021015825A/es unknown
-
2019
- 2019-02-14 JP JP2019024364A patent/JP6896781B2/ja active Active
- 2019-03-11 US US16/298,474 patent/US20190201535A1/en active Pending
-
2020
- 2020-03-25 US US16/829,659 patent/US20200297855A1/en not_active Abandoned
- 2020-07-09 AU AU2020204608A patent/AU2020204608A1/en not_active Abandoned
-
2021
- 2021-06-09 JP JP2021096239A patent/JP2021152034A/ja active Pending
- 2021-10-19 CY CY20211100902T patent/CY1125697T1/el unknown
-
2022
- 2022-12-23 AU AU2022291595A patent/AU2022291595B2/en active Active
-
2025
- 2025-02-04 US US19/045,166 patent/US20250170245A1/en active Pending
- 2025-09-12 AU AU2025230794A patent/AU2025230794A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2021007I1 (no) | calcifediol | |
| DK3060229T3 (da) | Stabile, vandige antistofformuleringer | |
| CL2016000680A1 (es) | Formulaciones de anticuerpos anti-pdl1. | |
| EP3065716C0 (en) | FORMULATIONS | |
| FR3006466B3 (fr) | . | |
| DK3052080T3 (da) | Langtidsvirkende spiro-isoxalin-formuleringer | |
| EP2975063A4 (en) | LOW SUBSTITUTED CELLULOSE ACETATE | |
| DK3077047T3 (da) | Aramcholsalte | |
| DK3052081T3 (da) | Pastil | |
| DK3060460T3 (da) | Saddel | |
| DK3027598T3 (da) | Oxoquinazolinyl-butanamidderivater | |
| HRP20171890T1 (hr) | Supstituirani imidazopiridazini | |
| DK2956698T3 (da) | Bindestrimler | |
| DK2975030T3 (da) | Dihydropyridazin-3,5-dion-derivat | |
| CL2014000227S1 (es) | Decodificador | |
| DK3044389T3 (da) | Vinduespost-tværstykke-konstruktion | |
| DK2946640T3 (da) | Langmuir-probe | |
| EP2943489A4 (en) | DEUTERATED MOMELOTINIB | |
| DE102013106534B8 (de) | Chromatographiepipettenspitze | |
| EP3070792A4 (en) | LASER | |
| EP2970310A4 (en) | 5-BROMO-indirubins | |
| EP2853297A4 (en) | kendama | |
| FR3001302B1 (fr) | . | |
| DK3071227T3 (da) | Fiskevaccine | |
| HUE050917T2 (hu) | Hidrokortizon-tartalmú készítmény |